Sanofi on Thursday became the last major insulin maker to cut the price of the life-saving drug. Here's why it's been so expensive and what's next.

Sanofi is cutting the list price of Lantus, its most widely prescribed insulin in the US, by 78% and establishing a $35 monthly cap for those with private insurance, the company announced Thursday ...

Sanofi SNY announced up to a 78% cut in the list price of its most popular insulin, Lantus, following the likes of rival Novo Nordisk NVO and Eli Lilly LLY. Similar to Lilly, Sanofi also said it ...

A third drug company is cutting the price of insulin to $35, following competitors Eli Lilly and Novo Nordisk in heeding pressure from the Biden administration.

Sanofi has followed in the footsteps of its rivals in the US insulin market with a 78% price cut for its most widely-used Lantus product starting next January. It will restrict out-of-pocket costs ...

Lantus 100iu - 3 ml Injection (Insulin Glargine) drug information. Find its price or cost, dose, when to use, how to use, side effects, adverse effects, substitutes . It is manufactured by Sanofi ...

Health policy experts say Eli Lilly's competitors—Sanofi, which makes Apidra and Lantus, and Novo Nordisk, which makes NovoLog and Levemir—are now facing increasing pressure to respond.

French pharmaceutical company Sanofi, one of the top three insulin manufacturers for the U.S., announced on Thursday it would be cutting the list price for its most prescribed insulin product Lantu… ...

Over that period, Sanofi tripled the price of its Lantus insulin to about $275 per vial. A 2018 study estimated it costs roughly $2 to $4 to produce a vial of analog insulin, the type used by most ...